Oppenheimer analyst Leland Gershall reiterated an Outperform rating on Capricor Therapeutics (NASDAQ: CAPR).The analyst commented: "Briefing documents for this Wednesday's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Jones Trading on Capricor Therapeutics (CAPR): 'this is the first time we have seen the magnitude of difference in primary outcome'July 27, 2026 2:36 PM H.C. Wainwright on Capricor Therapeutics (CAPR): 'Cage Match Expected at Wednesday's AdCom as Drama with FDA Continues'July 27, 2026 12:31 PM